efavirenz / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12345678910111213...3940»
  • ||||||||||  Journal, Adverse drug reaction:  Determinants and outcomes of adverse drug reactions among people living with HIV on antiretroviral therapy in Nigeria. (Pubmed Central) -  Mar 13, 2026   
    Some (22%) of the patients recovered from ADRs; 1.2% were fatal, while 71.5% outcomes were unknown. ADRs were common among ART patients in Nigeria., with female gender, older age and types of ART regimen being major determinants of ADRs Active surveillance is necessary to ensure early detection of ADRs among patients on ART and thereby prevent ART-associated morbidity and mortality.
  • ||||||||||  Symfi (efavirenz/lamivudine/tenofovir disoproxil fumarate) / Viatris, tenofovir disoproxil fumarate / Generic mfg., efavirenz / Generic mfg.
    Observational data, Retrospective data, Journal, Real-world evidence:  Effectiveness and safety of ainuovirine plus lamivudine and tenofovir DF in virologically suppressed people living with HIV-1: the 48-week results of a multicenter, real-world study. (Pubmed Central) -  Mar 8, 2026   
    Although efavirenz (EFV)-based regimens have been widely used, current guidelines recommend integrase strand transfer inhibitor (INSTI)-based therapy as first-line...Virologically suppressed adults on a tenofovir disoproxil fumarate (TDF)/3TC+EFV regimen were either switched to TDF/3TC+ANV (ANV group) based on the physician's discretion or continued on TDF/3TC+EFV (EFV group)...Switching from EFV- to an ANV-based regimen effectively maintained VS and led to improved metabolic parameters, including less weight gain and a more favorable lipid profile. As an alternative switch strategy, the ANV-based regimen may be a more beneficial option for people living with HIV (PLWH) who are at high risk of weight-related or dyslipidemia-associated comorbidities.
  • ||||||||||  efavirenz / Generic mfg., Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial. (Pubmed Central) -  Mar 7, 2026   
    P=N/A
    As an alternative switch strategy, the ANV-based regimen may be a more beneficial option for people living with HIV (PLWH) who are at high risk of weight-related or dyslipidemia-associated comorbidities. Given that more than half had an ART regimen predicted to be fully active, most viraemia in children and adolescents could not be explained by resistance.Registration: The GIVE MOVE trial was registered on Clinicaltrials.gov NCT04233242.
  • ||||||||||  efavirenz / Generic mfg., Zepsun (donafenib) / Suzhou Zelgen
    Preclinical, Journal:  Development of an UPLC-MS/MS method for quantification of donafenib and its metabolite in rat plasma: application to drug-drug interaction. (Pubmed Central) -  Feb 19, 2026   
    In vivo, the AUC(0-t), AUC(0-?) and Cmax of donafenib and donafenib N-oxide were significantly increased in the presence of efavirenz, which indicated that efavirenz increased the exposure of donafenib in rats. In short, this UPLC-MS/MS method was reliable for quantifying donafenib and its metabolite, and the findings suggested that efavirenz had an inhibitory effect on the metabolism of donafenib in vitro and in vivo.
  • ||||||||||  efavirenz / Generic mfg., Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Late-Onset Efavirenz-Induced Liver Toxicity in a 17-Year-Old, Filipino, Patient With HIV. (Pubmed Central) -  Feb 16, 2026   
    Treatment involved corticosteroids, immunosuppressants, and switching to dolutegravir, leading to resolution. This is the first documented case in the Philippines of delayed-onset efavirenz-induced liver injury, underscoring the importance of ongoing liver monitoring during antiretroviral therapy.
  • ||||||||||  efavirenz / Generic mfg.
    Journal:  Distinct biochemical phenotypes of HIV exposed infants driven by antiviral medication. (Pubmed Central) -  Feb 12, 2026   
    The metabolomic differences between HEU participants and controls reflect perturbed pathways of steroids, tryptophan and bile acids, and they largely consisted of metabolites that were correlated with efavirenz concentrations within the HEU group. The results suggest a major contribution of the drug to the abnormal biochemical profile of HEU infants born to mothers treated with efavirenz.
  • ||||||||||  Review, Journal:  Triple drug co-delivery within nanosystems for synergistic anti-infective, anti-inflammatory, antinociceptive and neuroregenerative therapeutic effects: a focus on pharmacological and nanotechnological aspects. (Pubmed Central) -  Feb 5, 2026   
    Triple drug co-encapsulation has been achieved for non-steroidal anti-inflammatory drugs such as indomethacin, analgesic and antipyretic drugs such as paracetamol, immunosuppressant drugs such as methotrexate, antiretroviral drugs such as efavirenz, lopinavir, ritonavir, and tenofovir, antibacterial drugs such as amoxicillin and clarithromycin, antiulcer drugs such as omeprazole and famotidine, ion channel antagonists such as lomerizine hydrochloride, oxidized adenosine triphosphate, and zonampanel monohydrate, photosensitive molecules such as indocyanine green, genetic material such as MMP-9 siRNA, enzymes such as catalase, and/or plant-derived bioactive compounds such as curcumin, resveratrol, sinomenine, and thymoquinone. These molecules' triple co-encapsulation into nanometric formulations has led to controlled and sustained drug release, extended circulation time, enhanced bioavailability, and reduced systemic toxicity, with an overall improvement in drug targeting and therapeutic outcomes in rheumatoid arthritis, psoriasis and other inflammation-based conditions, HIV and Helicobacter pylori infection, and trauma-induced central nervous system secondary degeneration, ultimately opening a door for improved patient compliance due to simplified dosing regimens.
  • ||||||||||  chloroquine phosphate / Generic mfg., efavirenz / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg.
    Journal:  Incident hypertension among adults on ART in Malawi: a nested cohort study. (Pubmed Central) -  Jan 28, 2026   
    Identified predictors may help targeting screening. A newly observed protective effect of TS prophylaxis on incident hypertension needs confirmation.
  • ||||||||||  efavirenz / Generic mfg., dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Blood pressure, weight change and incident hypertension after switching to dolutegravir in treatment-experienced people living with HIV. (Pubmed Central) -  Jan 28, 2026   
    P=N/A
    Following the initial increase in BW on TLE, a larger increase in BP and a higher risk of incident hypertension was associated with switching antiretroviral therapy from TLE to TLD. Focussing on BP control while on DTG and timely initiation of antihypertensive drug therapy can help to reduce the burden of hypertension in PWH with their inherent increased cardiovascular risk.
  • ||||||||||  efavirenz / Generic mfg.
    Preclinical, Journal:  Efavirenz Interacts with Hormones Involved in Appetite and Satiety, Affecting Body Weight in Mice. (Pubmed Central) -  Jan 28, 2026   
    According to our findings, mice treated with EFV showed a decrease in body weight, despite increased food intake resulting from appetite stimulation, which is caused by specific compounds, hormones, and neural signals acting on the brain's hunger centres, primarily in the hypothalamus, promoting eating behaviours. However, further studies are necessary to investigate the mechanisms of EFV's effects on energy expenditure.
  • ||||||||||  phenytoin / Generic mfg., efavirenz / Generic mfg., warfarin / Generic mfg.
    Journal:  Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants. (Pubmed Central) -  Jan 20, 2026   
    This inhibition may increase the risk of adverse effects from narrow-therapeutic-index CYP2C9 substrates (e.g., warfarin, phenytoin, and sulfonylureas). Therefore, therapeutic drug monitoring and dose adjustments are warranted when efavirenz is co-administered with these medications.
  • ||||||||||  efavirenz / Generic mfg., raltegravir / Generic mfg.
    Journal:  Efavirenz-Induced Hepatitis Mimicking Autoimmune Hepatitis: A Case Report. (Pubmed Central) -  Jan 19, 2026   
    Following Efavirenz withdrawal, liver enzymes, IgG, and ANA levels normalized, and liver stiffness on FibroScan improved. This case highlights the challenge of distinguishing autoimmune hepatitis from drug-induced liver injury when autoimmune markers are present and emphasizes the importance of considering late ART toxicity, as timely drug withdrawal can lead to full recovery without immunosuppression.
  • ||||||||||  efavirenz / Generic mfg.
    Journal:  A Non-Antigenic Randomized Polyethylene Glycol/Poly(2-Phenyl-2-Oxazine)-Based Drug Delivery Platform. (Pubmed Central) -  Dec 24, 2025   
    The formulations exhibit a distinct correlation between the solubilization of Efavirenz and the systematically varied rPEG composition, ranging from outstanding to moderate micelle drug loading capacities...Competitive enzyme-linked immunosorbent assays (ELISA) revealed a pronounced reduction in APA affinity in comparison to PEG. Taken together, the synergistic combination of rPEG and PPheOzi establishes a non-antigenic micellar platform capable of achieving high drug loadings.
  • ||||||||||  Journal:  HIV Viral Rebound on Dolutegravir, Lopinavir and Efavirenz: National Program Data Analysis from Ukraine. (Pubmed Central) -  Dec 17, 2025   
    Favorable performance of DTG compared with other first-line ART options in sustaining VS supports continued roll-out of DTG-based regimens. High overall incidence of viral rebound, including on DTG-based regimens, calls for targeted evidence-based adherence support interventions and improved viral load and drug resistance monitoring, especially among high-risk populations.
  • ||||||||||  efavirenz / Generic mfg., rifampicin / Generic mfg., Vemlidy (tenofovir alafenamide) / Gilead
    PK/PD data, Journal:  The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in Participants with HIV-associated Tuberculosis. (Pubmed Central) -  Dec 2, 2025   
    High-level resistance to efavirenz supports transitioning to dolutegravir-based first-line regimens and highlights the importance of supporting key populations in accessing and adhering to ART to prevent the spread of drug-resistant HIV. When combined with rifampicin, ART containing standard-dose TAF resulted in higher TFV-DP concentrations than TDF-based ART in participants with HIV-associated tuberculosis, supporting its use with rifampicin-containing tuberculosis therapy.
  • ||||||||||  efavirenz / Generic mfg.
    Preclinical, Journal:  CYP46A1 Activation Improves Retinal Neovascularization in a Mouse Model of Retinopathy of Prematurity. (Pubmed Central) -  Nov 24, 2025   
    Seven-day-old (P7) C57BL/6J mice maintained in room air (controls) or subjected to oxygen-induced retinopathy (OIR) were treated with/without 20 mg/kg efavirenz (EFV), a CYP46A1 activator administered intraperitoneally from P7 to P17...The current study demonstrates the developmental regulation of CYP46A1 and the dysregulated expression and levels of the downstream metabolite 24-Hydroxycholesterol (24HC) in OIR mice. The study further suggests that pharmacological CYP46A1 activation may improve key pathological features associated with pathological neovascularization in OIR mice.
  • ||||||||||  efavirenz / Generic mfg., cyclophosphamide / Generic mfg., methadone / Generic mfg.
    Journal:  CYP2B6 downregulation by cell-penetrating dominant-negative activating transcription factor 5 peptide in glioblastoma cells. (Pubmed Central) -  Nov 23, 2025   
    SIGNIFICANCE STATEMENT: The study found that the transcription factor activating transcription factor 5 regulates CYP2B6 expression in glioblastoma cell lines. Introducing a transactivator of transcription-fused cell-penetrating dominant-negative activating transcription factor 5 peptide downregulates CYP2B6 protein expression, suggesting its potential for personalized dosing strategies by targeting CYP2B6.
  • ||||||||||  tenofovir disoproxil fumarate / Generic mfg., efavirenz / Generic mfg.
    Journal:  Compare antiretroviral drug concentrations in hair and plasma across EFV-based regimens in China. (Pubmed Central) -  Nov 16, 2025   
    These findings demonstrate that BIC/FTC/TAF is an effective and metabolically favorable treatment option for PLWH switching from LPV/r based regimens, regardless of whether they have a prior history of virological failure. A cohort study in which HIV-infected adults receiving tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + efavirenz (EFV) regimen for at 6 months were recruited and paired hair and plasma samples collected at about 6